Evidence map›Paper›PMID 38505941›Full record

ArticleStatistical methods in medical research2024

Optimal allocation strategies in platform trials with continuous endpoints.

Marta Bofill Roig, Ekkehard Glimm, Tobias Mielke, Martin Posch

Open access · hybridAbstract read
In one paragraph

Article in Statistical methods in medical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

Marta Bofill RoigSection for Medical Statistics, Center for Medical Data Science, Medical University of Vienna, Wien, Austria.ORCID 0000-0002-4400-7541
Ekkehard GlimmAdvanced Methodology and Data Science, Novartis Campus, Novartis Pharma AG, Basel, Switzerland.ORCID 0000-0003-3624-961X
Tobias MielkeStatistics and Decision Sciences, Janssen-Cilag GmbH, Neuss, Nordrhein-Westfalen, Germany.
Martin PoschSection for Medical Statistics, Center for Medical Data Science, Medical University of Vienna, Wien, Austria.
Medical University of Vienna · ATJanssen (Germany) · DENovartis (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Platform trials are randomized clinical trials that allow simultaneous comparison of multiple interventions, usually against a common control. Arms to test experimental interventions may enter and leave the platform over time. This implies that the number of experimental intervention arms in the trial may change as the trial progresses. Determining optimal allocation rates to allocate patients to the treatment and control arms in platform trials is challenging because the optimal allocation depends on the number of arms in the platform and the latter typically varies over time. In addition, the optimal allocation depends on the analysis strategy used and the optimality criteria considered. In this article, we derive optimal treatment allocation rates for platform trials with shared controls, assuming that a stratified estimation and a testing procedure based on a regression model are used to adjust for time trends. We consider both, analysis using concurrent controls only as well as analysis methods using concurrent and non-concurrent controls and assume that the total sample size is fixed. The objective function to be minimized is the maximum of the variances of the effect estimators. We show that the optimal solution depends on the entry time of the arms in the trial and, in general, does not correspond to the square root of

Indexed as

Randomized Controlled Trials as TopicAdaptive Clinical Trials as TopicEndpoint DeterminationHumansModels, StatisticalResearch DesignSample Sizeoptimal allocationPlatform trialshared controlstime trends

Identifiers

PMID38505941
PMCPMC11041082
OpenAlexW4393008400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.